Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

ffer materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... of the ResMed Data Exchange program, a comprehensive ... medical equipment (HME) and other health care providers. ... secure access to critical patient information. It integrates ... AirView™ and U-Sleep™ patient management platforms with customers, ...
(Date:10/20/2014)... PRINCETON, N.J. , Oct. 20, 2014 /PRNewswire/ ... Taiho Pharmaceutical Co., Ltd. ( Japan ... Administration (FDA) granted Fast Track designation for TAS-102 ... combination anticancer drug under investigation for the treatment ... the Company has initiated a rolling NDA submission ...
(Date:10/20/2014)... October 20, 2014 Norgine B.V. ... novel, low volume bowel preparation, NER1006, presented at the ... College of Gastroenterology (ACG), Philadelphia, PA ... stool weight and co-primary endpoint of cleansing success. The ... vs. MOVIPREP ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will ... Tuesday, February 15, 2011.  The presentation is scheduled for ... through the Company,s web site, www.regeneron.com , on ... presentation will be available after the live webcast through ...
... Feb. 8, 2011 IPC The Hospitalist Company, Inc. (Nasdaq: ... practice company, announced today that it will report results for ... Monday, March 7, 2011, after the market close. ... 5:00 p.m. ET (2:00 p.m. PT) on March 7, 2011 ...
Cached Medicine Technology:IPC The Hospitalist Company, Inc. to Report Fourth Quarter 2010 Results 2
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, ... of Columbus, Inc., A Division of MaternOhio Clinical Associates, ... than 100,000 patients annually. Dr. Murphy will provide a ... of a women’s life. She is accepting new patients ... and Dublin. , Dr. Murphy offers a wide variety ...
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... , CHADDS FORD, Pa., Aug. 31 Endo Pharmaceuticals (Nasdaq: ... Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. ... and development programs. , , The presentation will be webcast ... under the investors section. , , ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... is over-treatment for many men, researchers say , MONDAY, Aug. ... a test for prostate-specific antigen (PSA) has led to mass ... PSA screening test came into use in 1986, federal government ... the United States has risen substantially, said the report in ...
... 31 (HealthDay News) -- Walk-in retail clinics staffed by nurse ... has found. , Writing in the Sept. 1 issue of ... Ateev Mehrotra said that retail clinics -- which are typically ... other retail chain stores such as Target and Wal-Mart -- ...
... , , ABBOTT PARK, Ill., Aug. ... the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, ... financial officer, will make a presentation on the company at 8:10 ... webcast of the presentation will be accessible through Abbott,s Investor Relations ...
... as fires threaten , , WASHINGTON, Aug. 31 ... evacuees a safe place to stay as wildfires in California force people ... took refuge from the smoke and fire in Red Cross shelters. ... , "If you are ordered to leave your home, please ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Prostate Cancer Over-Diagnosed: Study 2Health News:Prostate Cancer Over-Diagnosed: Study 3Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3
... Farnsworth panel D15 test evaluation has ... to arrange caps with automatic creation ... manual color deficiency analysis, calculation of ... age-corrected CCI, eye selection (OD, OS, ...
... test is used to separate ... vs normal. Farnsworth D15 come ... the patient to select the ... box is closed and the ...
HRR/Amsler book combo with occluding glasses....
Ishihara test chart book for color blindness. 14 plate. A simple accurate method for discovering congenital color blindness....
Medicine Products: